Cargando…

NRF2 participates in the suppressive tumor immune microenvironment of KRAS/KEAP1 co-mutant non-small cell lung cancer by inhibiting the STING pathway

Detalles Bibliográficos
Autores principales:	Xiaodan, Sun, Peiyan, Zhao, Hui, Li, Yan, Liu, Ying, Cheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Chongqing Medical University 2022
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363618/ https://www.ncbi.nlm.nih.gov/pubmed/37492744 http://dx.doi.org/10.1016/j.gendis.2022.10.009

Ejemplares similares

Immunoediting of KEAP1-NRF2 mutant tumours is required to circumvent NRF2-mediated immune surveillance
por: Baird, Liam, et al.
Publicado: (2023)

Mild Oxidative Stress Reduces NRF2 SUMOylation to Promote Kras/Lkb1/Keap1 Mutant Lung Adenocarcinoma Cell Migration and Invasion
por: Xu, Jiaqian, et al.
Publicado: (2020)

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Wang, Jieqiong, et al.
Publicado: (2016)

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
por: Adderley, Helen, et al.
Publicado: (2019)

A CRISPR screen identifies redox vulnerabilities for KEAP1/NRF2 mutant non-small cell lung cancer
por: Jiang, Chang, et al.
Publicado: (2022)

Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer
por: Zhong, Longhui, et al.
Publicado: (2020)

Parkes Weber syndrome with lymphedema caused by a somatic KRAS variant
por: Eng, Whitney, et al.
Publicado: (2021)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Mutant KRAS Exosomes Influence the Metabolic State of the Colon Microenvironment
por: Preet, Ranjan, et al.
Publicado: (2018)

Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
por: Dias Carvalho, Patrícia, et al.
Publicado: (2019)

The KEAP1–NRF2 System in Cancer
por: Taguchi, Keiko, et al.
Publicado: (2017)

Keap1/Nrf2 Signaling Pathway
por: Sykiotis, Gerasimos P.
Publicado: (2021)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

CircKEAP1 Suppresses the Progression of Lung Adenocarcinoma via the miR-141-3p/KEAP1/NRF2 Axis
por: Wang, Yanbo, et al.
Publicado: (2021)

Immunogenomic classification of lung squamous cell carcinoma characterizes tumor immune microenvironment and predicts cancer therapy
por: Fu, Denggang, et al.
Publicado: (2023)

FSP1 confers ferroptosis resistance in KEAP1 mutant non-small cell lung carcinoma in NRF2-dependent and -independent manner
por: Kim, Jong Woo, et al.
Publicado: (2023)

Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
por: Singh, Anju, et al.
Publicado: (2006)

m(6)A regulator-mediated methylation modification patterns and tumor immune microenvironment characterization in endometrial cancer
por: Li, Kexin, et al.
Publicado: (2023)

Transcriptomic analysis identifies a pan-cancer association of IL27 expression with cancer prognosis and immune microenvironment
por: Liao, Kaili, et al.
Publicado: (2022)

Small molecular inhibitors for KRAS-mutant cancers
por: Wu, Xuan, et al.
Publicado: (2023)

STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer
por: Lee, Seung Joon, et al.
Publicado: (2021)

Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ
por: Liu, Yi, et al.
Publicado: (2022)

Structural basis of Keap1 interactions with Nrf2
por: Canning, Peter, et al.
Publicado: (2015)

Epigenetic Regulation of NRF2/KEAP1 by Phytochemicals
por: Bhattacharjee, Shamee, et al.
Publicado: (2020)

The KEAP1/NRF2 Signaling Pathway in Keratinization
por: Ishitsuka, Yosuke, et al.
Publicado: (2020)

The KEAP1-NRF2 System and Esophageal Cancer
por: Hirose, Wataru, et al.
Publicado: (2022)

Modulation of NRF2/KEAP1 Signaling in Preeclampsia
por: Tossetta, Giovanni, et al.
Publicado: (2023)

Pancreatic cyst fluid harboring a KRAS mutation
por: Al-Turkmani, M. Rabie, et al.
Publicado: (2019)

Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS
por: Kalvala, Arjun, et al.
Publicado: (2019)

Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer
por: Yang, Jiawen, et al.
Publicado: (2021)

Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer
por: Li, Yunchang, et al.
Publicado: (2022)

Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer
por: Wagner, Steve, et al.
Publicado: (2018)

BRD4 Targets the KEAP1-Nrf2-G6PD Axis and Suppresses Redox Metabolism in Small Cell Lung Cancer
por: Lv, Yang, et al.
Publicado: (2022)

KEAP1 and done? Targeting the NRF2 pathway with sulforaphane
por: Dinkova-Kostova, Albena T., et al.
Publicado: (2017)

WDR23 regulates NRF2 independently of KEAP1
por: Lo, Jacqueline Y., et al.
Publicado: (2017)

Coumarins as Modulators of the Keap1/Nrf2/ARE Signaling Pathway
por: Hassanein, Emad H. M., et al.
Publicado: (2020)

Nrf2/Keap1/ARE signaling: Towards specific regulation
por: Ulasov, Alexey V., et al.
Publicado: (2022)

The KEAP1-NRF2 System in Healthy Aging and Longevity
por: Matsumaru, Daisuke, et al.
Publicado: (2021)

Molecular Basis of the KEAP1-NRF2 Signaling Pathway
por: Suzuki, Takafumi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mitct3k26ro4uu4n3gd26hh5mt